Clinicopathological analysis has revealed that patients with high SALL4 expression in HCC have a worse prognosis than those with low expression (Zeng et al. 2014; Wang et al. 2017; Leake 2013; Jung et al. 2022). This evidence concerns the gene SALL4 and hepatocellular carcinoma.